Literature DB >> 7705493

Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity.

C R Davies1, E A Llanos-Cuentas, S D Pyke, C Dye.   

Abstract

A prospective longitudinal survey of cutaneous leishmaniasis (Leishmania peruviana) was carried out in Peru on a study population of 4716 persons living in 38 villages (Departments of Lima, Ancash and Piura). Demographic and clinical data were collected from all individuals, and a Montenegro skin test (MST) was carried out on 72% (3418) of the study population. Each household was revisited at 3-monthly intervals for up to 2 years to detect new leishmaniasis cases; 497 people received a second MST at the end of the study. Analysis of the epidemiological data indicated that (i) 17% (16/94) of all infections were subclinical, (ii) this percentage increased significantly with age, (iii) clinical infections led to 73.9% protective immunity (95% C.I. 53.0-85.5%) and relatively permanent MST responsiveness (recovery rate = 0.0098/year; 95% C.I. 0.000-0.020/year), (iv) sub-clinical infections led to protective immunity, which was positively correlated with their MST induration size (increasing by 17.9% per mm; P < 0.0001), and a mean MST recovery rate of 0.114/year (4/421 man-months), and (v) recurrent leishmaniasis was dominated by reactivations, not by reinfections.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705493      PMCID: PMC2271273          DOI: 10.1017/s0950268800057964

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  36 in total

Review 1.  Molecular determinants of Leishmania virulence.

Authors:  K P Chang; G Chaudhuri; D Fong
Journal:  Annu Rev Microbiol       Date:  1990       Impact factor: 15.500

2.  Leishmania (Viannia) peruviana isolated from the sandfly Lutzomyia peruensis (Diptera: Psychodidae) and a sentinel hamster in the Huayllacallán Valley, Ancash, Peru.

Authors:  J E Perez; P Villaseca; A Caceres; M Lopez; A Zolessi; M Campos; H Guerra; A Llanos-Cuentas
Journal:  Trans R Soc Trop Med Hyg       Date:  1991 Jan-Feb       Impact factor: 2.184

Review 3.  Leishmaniasis epidemiology: the theory catches up.

Authors:  C Dye
Journal:  Parasitology       Date:  1992       Impact factor: 3.234

4.  Induction and modulation of the immune response to Leishmania by Montenegro's skin test.

Authors:  M D Nascimento; N M Alcântara-Neves; M E Muniz; S F Nunes; M Paranhos; L C de Carvalho
Journal:  Trans R Soc Trop Med Hyg       Date:  1993 Jan-Feb       Impact factor: 2.184

5.  Association of mucosal leishmaniasis with HLA.

Authors:  M L Petzl-Erler; M P Belich; F Queiroz-Telles
Journal:  Hum Immunol       Date:  1991-12       Impact factor: 2.850

6.  Correlation between histopathology, immune response, clinical presentation, and evolution in Leishmania braziliensis infection.

Authors:  Y Gutierrez; G H Salinas; G Palma; L B Valderrama; C V Santrich; N G Saravia
Journal:  Am J Trop Med Hyg       Date:  1991-09       Impact factor: 2.345

7.  Recurrent cutaneous leishmaniasis: a role for persistent parasites?

Authors:  T Aebischer
Journal:  Parasitol Today       Date:  1994-01

8.  Epidemiology of cutaneous leishmaniasis in Colombia: a longitudinal study of the natural history, prevalence, and incidence of infection and clinical manifestations.

Authors:  K A Weigle; C Santrich; F Martinez; L Valderrama; N G Saravia
Journal:  J Infect Dis       Date:  1993-09       Impact factor: 5.226

9.  An outbreak of American cutaneous leishmaniasis (Leishmania braziliensis braziliensis) in a periurban area of Rio de Janeiro city, Brazil: clinical and epidemiological studies.

Authors:  M P Oliveira-Neto; C Pirmez; E Rangel; A Schubach; G Grimaldi Júnior
Journal:  Mem Inst Oswaldo Cruz       Date:  1988 Oct-Dec       Impact factor: 2.743

10.  Lutzomyia verrucarum can transmit Leishmania peruviana, the aetiological agent of Andean cutaneous leishmaniasis.

Authors:  C R Davies; M Fernandez; L Paz; N Roncal; A Llanos-Cuentas
Journal:  Trans R Soc Trop Med Hyg       Date:  1993 Sep-Oct       Impact factor: 2.184

View more
  32 in total

1.  Characterization of regulatory T cell (Treg) function in patients infected with Leishmania braziliensis.

Authors:  Diego L Costa; Luiz H Guimarães; Thiago M Cardoso; Adriano Queiroz; Ednaldo Lago; Ana M Roselino; Olívia Bacellar; Edgar M Carvalho; João S Silva
Journal:  Hum Immunol       Date:  2013-08-28       Impact factor: 2.850

2.  Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia.

Authors:  A Sassi; H Louzir; A Ben Salah; M Mokni; A Ben Osman; K Dellagi
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

3.  Clinical cutaneous leishmaniasis rates are associated with household Lutzomyia gomezi, Lu. Panamensis, and Lu. trapidoi abundance in Trinidad de Las Minas, western Panama.

Authors:  Azael Saldaña; Luis F Chaves; Chystrie A Rigg; Coridalia Wald; Joanne E Smucker; Jose E Calzada
Journal:  Am J Trop Med Hyg       Date:  2013-01-21       Impact factor: 2.345

4.  Impaired Th1 Response Is Associated With Therapeutic Failure in Patients With Cutaneous Leishmaniasis Caused by Leishmania braziliensis.

Authors:  Augusto M Carvalho; Luiz H Guimarães; Rúbia Costa; Maíra G Saldanha; Iana Prates; Lucas P Carvalho; Sérgio Arruda; Edgar M Carvalho
Journal:  J Infect Dis       Date:  2021-02-13       Impact factor: 5.226

5.  T-bet, GATA-3, and Foxp3 expression and Th1/Th2 cytokine production in the clinical outcome of human infection with Leishmania (Viannia) species.

Authors:  Yira Rosalba Díaz; Ricardo Rojas; Liliana Valderrama; Nancy Gore Saravia
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

6.  Evidence for a major gene controlling susceptibility to tegumentary leishmaniasis in a recently exposed Bolivian population.

Authors:  A Alcaïs; L Abel; C David; M E Torrez; P Flandre; J P Dedet
Journal:  Am J Hum Genet       Date:  1997-10       Impact factor: 11.025

7.  Endemic transmission of visceral leishmaniasis in Bhutan.

Authors:  Thinley Yangzom; Israel Cruz; Caryn Bern; Daniel Argaw; Margriet den Boer; Iván Dario Vélez; Sujit K Bhattacharya; Ricardo Molina; Jorge Alvar
Journal:  Am J Trop Med Hyg       Date:  2012-10-22       Impact factor: 2.345

8.  Immunologic Markers of Protection in Leishmania (Viannia) braziliensis Infection: A 5-Year Cohort Study.

Authors:  Aline C Muniz; Olívia Bacellar; Ednaldo Lima Lago; Augusto M Carvalho; Pedro Paulo Carneiro; Luiz Henrique Guimarães; Paulo N Rocha; Lucas P Carvalho; Marshall Glesby; Edgar M Carvalho
Journal:  J Infect Dis       Date:  2016-05-18       Impact factor: 5.226

9.  The Elderly Respond to Antimony Therapy for Cutaneous Leishmaniasis Similarly to Young Patients but Have Severe Adverse Reactions.

Authors:  Alexsandro Souza do Lago; Maurício Nascimento; Augusto M Carvalho; Neuza Lago; Juliana Silva; José Roberto Queiroz; Lucas P Carvalho; Albert Schriefer; Mary Wilson; Paulo Machado; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2018-03-22       Impact factor: 2.345

10.  First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony.

Authors:  Cesar Miranda-Verastegui; Gianfranco Tulliano; Theresa W Gyorkos; Wessmark Calderon; Elham Rahme; Brian Ward; Maria Cruz; Alejandro Llanos-Cuentas; Greg Matlashewski
Journal:  PLoS Negl Trop Dis       Date:  2009-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.